Characterization of the effect of the GLUT-1 inhibitor BAY-876 on T cells and macrophages.
暂无分享,去创建一个
U. Hofmann | M. Delgobo | G. Ramos | M. Vaeth | M. Eckstein | Ziyi Chen | Stefan Frantz | N. Gladow
[1] Xiaoxi Wang,et al. Identification of a novel GLUT1 inhibitor with in vitro and in vivo anti-tumor activity. , 2022, International journal of biological macromolecules.
[2] F. Schumacher,et al. The glucose transporter GLUT3 controls T helper 17 cell responses through glycolytic-epigenetic reprogramming. , 2022, Cell metabolism.
[3] Jan Dudek,et al. Pharmacological Inhibition of GLUT1 As a New Immunotherapeutic Approach After Myocardial Infarction. , 2021, Biochemical pharmacology.
[4] F. Martel,et al. The in vitro effect of the diabetes-associated markers insulin, leptin and oxidative stress on cellular characteristics promoting breast cancer progression is GLUT1-dependent. , 2021, European journal of pharmacology.
[5] Kellen L. Olszewski,et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer , 2020, Nature Cell Biology.
[6] D. Mann,et al. Reappraising the role of inflammation in heart failure , 2020, Nature Reviews Cardiology.
[7] B. Haibe-Kains,et al. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer , 2019, Nature Communications.
[8] R. Diaz,et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.
[9] Shu-Wha Lin,et al. The Combination of MK-2206 and WZB117 Exerts a Synergistic Cytotoxic Effect Against Breast Cancer Cells , 2019, Front. Pharmacol..
[10] H. Saya,et al. Glucose transporter 1‐mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors , 2019, Journal of controlled release : official journal of the Controlled Release Society.
[11] F. Setién,et al. Epigenetic loss of the endoplasmic reticulum-associated degradation inhibitor SVIP induces cancer cell metabolic reprogramming. , 2019, JCI insight.
[12] Brian J. Bennett,et al. Myeloid Slc2a1-Deficient Murine Model Revealed Macrophage Activation and Metabolic Phenotype Are Fueled by GLUT1 , 2019, The Journal of Immunology.
[13] X. Fang,et al. Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876 , 2018, Cancers.
[14] A. Annoni,et al. Detection and Characterization of CD8+ Autoreactive Memory Stem T Cells in Patients With Type 1 Diabetes , 2018, Diabetes.
[15] H. Huthoff,et al. Upregulation of Glucose Uptake and Hexokinase Activity of Primary Human CD4+ T Cells in Response to Infection with HIV-1 , 2018, Viruses.
[16] P. Zhang,et al. Enhanced glycolysis contributes to the pathogenesis of experimental autoimmune neuritis , 2018, Journal of Neuroinflammation.
[17] P. Choudhary,et al. Dynamic Profiling of Insulin Secretion and ATP Generation in Isolated Human and Mouse Islets Reveals Differential Glucose Sensitivity , 2017, Cellular Physiology and Biochemistry.
[18] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[19] R. Curi,et al. A past and present overview of macrophage metabolism and functional outcomes. , 2017, Clinical science.
[20] J. Powell,et al. Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation , 2017, The Journal of Immunology.
[21] A. Carruthers,et al. WZB117 (2-Fluoro-6-(m-hydroxybenzoyloxy) Phenyl m-Hydroxybenzoate) Inhibits GLUT1-mediated Sugar Transport by Binding Reversibly at the Exofacial Sugar Binding Site* , 2016, The Journal of Biological Chemistry.
[22] F. Minutolo,et al. Anticancer agents interacting with membrane glucose transporters. , 2016, MedChemComm.
[23] T. Müller,et al. Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876 , 2016, ChemMedChem.
[24] E. Abraham,et al. Pyruvate Dehydrogenase Kinase 1 Participates in Macrophage Polarization via Regulating Glucose Metabolism , 2015, The Journal of Immunology.
[25] Susan R. Quinn,et al. Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. , 2015, Cell metabolism.
[26] J. Rathmell,et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. , 2014, Cell metabolism.
[27] M. Troester,et al. Metabolic Reprogramming of Macrophages , 2014, The Journal of Biological Chemistry.
[28] B. Faubert,et al. Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis , 2013, Cell.
[29] Liang Zheng,et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α , 2013, Nature.
[30] J. Rathmell,et al. Metabolic regulation of T lymphocytes. , 2013, Annual review of immunology.
[31] J. Licht,et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. , 2013, Immunity.
[32] Shiyong Wu,et al. A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo , 2012, Molecular Cancer Therapeutics.
[33] D. Green,et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. , 2011, Immunity.
[34] M. Dwyer,et al. Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation , 2011, Proceedings of the National Academy of Sciences.
[35] P. Sutphin,et al. Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality , 2011, Science Translational Medicine.
[36] D. Green,et al. HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells , 2011, The Journal of experimental medicine.
[37] J. Rathmell,et al. Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets , 2011, The Journal of Immunology.
[38] W. Paul,et al. Differentiation of effector CD4 T cell populations (*). , 2010, Annual review of immunology.
[39] J. Rathmell,et al. Glucose Uptake Is Limiting in T Cell Activation and Requires CD28-Mediated Akt-Dependent and Independent Pathways1 , 2008, The Journal of Immunology.
[40] C. Thompson,et al. The CD28 signaling pathway regulates glucose metabolism. , 2002, Immunity.
[41] H. Shinomiya,et al. Endotoxin-Induced Enhancement of Glucose Influx into Murine Peritoneal Macrophages via GLUT1 , 1995 .
[42] H. Liu,et al. Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. , 1994, Journal of immunology.
[43] A. Carruthers,et al. Equilibrium ligand binding to the human erythrocyte sugar transporter. Evidence for two sugar-binding sites per carrier. , 1987, The Journal of biological chemistry.